BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28772206)

  • 1. Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.
    Jing XM; Yu JR; Luo YK; Zhang SC; Liu JF; Li L; Wu P; Zhang ZH
    Leuk Res; 2017 Sep; 60():89-93. PubMed ID: 28772206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
    Qi SN; Li YX; Wang H; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Zhou LQ; Yu ZH
    Cancer; 2009 Nov; 115(21):4980-9. PubMed ID: 19634158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B-cell lymphoma in the rituximab era.
    Guan Q; Hong Y; Hu G; Zhou Q; Li L; Qian Z; Zhou S; Ren X; Qiu L; Wang X; Zhang H
    Hematol Oncol; 2021 Oct; 39(4):490-497. PubMed ID: 33908077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognosis analysis of primary breast diffuse large B cell lymphoma].
    Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
    Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
    Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved outcomes of localized diffuse large B-cell lymphoma at the Waldeyer ring in comparison to the sinonasal area in the rituximab era.
    Ma WL; Hong RL; Lou PJ; Yao M; Wu SJ; Lin CW; Wang CW; Chang CH; Cheng AL; Kuo SH
    Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38148602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients.
    Luo H; Yi P; Wang W; Li K; Meng L; Li J; Zeng W; Tang M
    Med Sci Monit; 2019 Nov; 25():8671-8682. PubMed ID: 31734687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
    Wang Y; Shi ZY; Shi Q; Wang S; Zhang MC; Shen R; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):321-327. PubMed ID: 37357002
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].
    Fu ZY; Zhu J; Song YQ; Liu WP; Ji XQ; Zhan SY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Jun; 46(3):405-11. PubMed ID: 24943019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waldeyer's ring lymphomas: a clinical study from the Comprehensive Cancer Center West population based NHL registry.
    Krol AD; Le Cessie S; Snijder S; Kluin-Nelemans JC; Kluin PM; Noorduk EM
    Leuk Lymphoma; 2001; 42(5):1005-13. PubMed ID: 11697617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
    Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
    Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?
    Başcı S; Yiğenoğlu TN; Bakırtaş M; Uncu Ulu B; Yaman S; Dal MS; Kızıl Çakar M; Altuntaş F
    Leuk Res; 2021 Mar; 102():106521. PubMed ID: 33582426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
    Wen J; Zhou J; Liu Z; Liu T; Xu C
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ki-67 proliferative index in non-Hodgkin's lymphoma and its clinical significance].
    Li J; Hu R; Liao AJ; Shi HY; Yan W; Liu ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):935-9. PubMed ID: 21867618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.